1. Introduction
Pancreatic cancer is a highly fatal disease with an approximately 10% 5-year survival rate all over the world. Its incidence is rising every year, making it an increasingly common cause of cancer-related deaths. Patients typically present with advanced disease due to lack of or vague symptoms when the cancer is still localized [1,2]. Surgery has remained the only curative treatment of pancreatic cancer for over a decade [1]. Unfortunately, in resectable pancreatic cancer patients who received surgery treatment, the prognosis was not very satisfactory, and local recurrence events ranged from 20% to 50% [3]. Thus, the treatment concept of pancreatic cancer has changed from simple surgery to comprehensive treatment.
The role of radiotherapy in improving the survival of patients with pancreatic cancer after radical surgery remains ambiguous. The Gastrointestinal Tumor Study Group (GITSG) demonstrated a significant survival advantage for patients who received adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. The median survival was 10.9 months in the control group compared to 21.0 months for those who randomly received the treatment. This survival benefit in the treatment group might be due to chemotherapy or radiotherapy or chemoradiotherapy [4]. The EORTC trial, a larger-powered study designed to validate the smaller GITSG trial results, used a similar adjuvant therapy, except it did not include chemotherapy. Patients with T1-2N0-1aM0 pancreatic head or T1-3N0-1aM0 periampullary cancer were included in the EORTC trial while pancreatic patients following curative resection were studied in the GITSG study. Unlike the GITSG trial, the EORTC trial did not find a statistically significant benefit to adjuvant chemoradiation [5]. However, through further analysis of pancreatic cancer subgroups, with one-sided log-rank test would have been used, the EORTC trial would have suggested a benefit to adjuvant chemoradiotherapy. Together with the results of the GITSG trial, there is vital phase III evidence that patients may benefit from adjuvant chemoradiotherapy [6]. In contrast, European ESPAC-1 trial concluded that adjuvant chemotherapy has a significant survival benefit in patients with resected pancreatic cancer, whereas adjuvant chemoradiotherapy has a deleterious effect on survival. This study has been questioned for grouping irregularity and not according with random selection [7]. The contradiction of the conclusions from different studies may be due to the lack of sufficient enrollment patients, no further screening of enrolled population, inconsistencies in treatment regimens and the differences in statisical methods. Recent retrospective analysis suggests that adjuvant radiotherapy may not be associated with an OS benefit for all patients, but for the subgroup with high risk factors, such as T4, N+ or R+ resection [8–10]. Based on NCCN guidelines, adjuvant radiotherapy was recommended in pancreatic cancer patients with N+ and R+ resection [11].
The conflicting conclusions from various studies highlight the need for more precise screening to identify patients who may benefit from adjuvant radiotherapy. Currently the role of adjuvant radiotherapy in pancreatic cancer after up-front radical surgery remains unclear. This retrospective study, based on a large-scale population database, aims to evaluate the efficacy of adjuvant radiotherapy for resectable pancreatic cancer after up-front radical surgery.
2. Materials and methods
2.1 Patient selection
The account was registered with the official SEER site and the SEER*Stat software was downloaded. The user ID is “19331-Nov2021”. The patient data for this study were extracted from the SEER database, which includes comprehensive cancer statistics for the U.S. population. The database contains detailed incidence and demographic info, such as race, age, marital status, median income, sex, year of diagnosis, primary site, T stage at diagnosis, N stage at diagnosis, the procedure of removal, biopsy, or aspiration of regional lymph nodes performed during the initial work-up or first course of therapy at all facilities (scope region lymph surgery), chemotherapy, radiotherapy, number of tumors and survival information. Patients were diagnosed as pancreatic cancer according to the Sixth Edition of the American Joint Committee on cancer (AJCC) staging manual (T1: localized within the pancreas, with diameter ≤ 2cm, T2: localized within the pancreas, with diameter > 2cm; T3: extends beyond the pancreas but not involving the celiac axis or superior mesenteric artery; T4: involving the celiac axis or superior mesenteric artery; N0: no regional lymph node metastasis; N1: regional lymph node metastasis; M0: no distant metastasis; M1: distant metastasis). The current study was conducted in accordance with the Declaration of Helsinki. Note that the requirement for informed consent was waived by the board, as the study utilized data extracted from the SEER database.
The inclusion criteria were as follows: patients diagnosed with M0 stage pancreatic cancer between 2004 and 2015. The exclusion criteria were as follows: (1) unknown T and N stage information; (2) patients without radical surgical treatment; (3) unknown whether performed radiotherapy or radiotherapy before or during surgery; received radiotherapy other than beam radiation; (4) unknown whether performed chemotherapy, or chemotherapy before or during surgery; (5) multiple primary carcinomas; (6) unknown the scope region lymph surgery; (7) age < 18; (8) unknown the cause of death; (9) non-ductal adenocarcinoma or unknown histological type (Fig 1).
[Figure omitted. See PDF.]
2.2 Definition of endpoints
The endpoints of the current study were overall survival (OS) and cancer-specific survival (CSS). OS was defined as the interval from the time patients were diagnosed with pancreatic cancer to the time of death from any cause. CSS was defined as the interval from the time patients were diagnosed with pancreatic to the time of death caused by cancer.
2.3 Statistical analysis
All statistical analyses were conducted using SPSS 25.0. All the variables were converted to categorical variables. The differences in these variables between the radiotherapy group and the non-radiotherapy group were evaluated using a chi-square test. Univariate and multivariate COX proportional hazard models were used to identify prognostic factors that influenced survival outcome. The survival outcomes of the two groups were compared using the log-rank test, and the survival curves were plotted using the Kaplan-Meier method.
To reduce selection bias and balance the baseline characteristics between the two groups, we conducted propensity score matching (PSM). All variables were included in the PSM analysis. A 1:1 matching ratio was used, with an optimal caliper of 0.02. Before PSM, 7097 pancreatic cancer patients were enrolled in this study. After PSM, a total of 4304 patients were included in the analysis. Subgroup survival analysis was conducted in the matched population. P values less than 0.05 were considered statistically significant.
3.Results
3. 1 Characteristics of patients
Before PSM, 7097 resectable pancreatic cancer patients were enrolled in this study. Among them, 2276 patients received adjuvant radiotherapy (beam radiation), 4821 did not receive adjuvant radiotherapy, 4673 received adjuvant chemotherapy, 2424 did not receive adjuvant chemotherapy, 2154 received adjuvant chemoradiotherapy, and 2302 received none of them. Most patients were white (80.91%) and aged over 60 years (70.34%). Additionally, 61.46% of patients were married, 53.05% had a median income over 65,000 USD, and 50.13% were men. Years of diagnosis between 2011 and 2015 accounted for 54.35%, and most of the tumors occurred in the head of the pancreas (72.89%), 76.61% were T3 stage, and 64.75% were N1 stage. All the patients received radical pancreatic cancer surgery. Age at diagnosis, marital status, sex, year of diagnosis, primary site of tumor location, T stage, N stage, and chemotherapy were unbalanced between the two groups (all p < 0.05).
After PSM, a total of 4,304 resectable pancreatic cancer patients were included in this study. 2,152 of these patients received adjuvant radiotherapy, while the other 2,152 did not. Additionally, 4,060 patients were administered adjuvant chemotherapy, compared to 244 who did not receive. A subset of 2,030 patients underwent both adjuvant chemotherapy and radiotherapy, while 122 patients did not receive either. The characteristics that shows a significant imbalance and remained unbalanced post-PSM, including N stage, and scope region lymph surgery, were statistically significant (all p < 0.05) as shown in the following Table 1.
[Figure omitted. See PDF.]
3.2 Predictors of OS and CSS before PSM
The variables were significantly correlated with survival outcome in the univariable Cox regression, including race, age, marital status, median income, year of diagnosis, primary site of tumor location, T stage, N stage, chemotherapy and radiotherapy (all p < 0.05). All variables from the univariable Cox regression were included in the multivariable Cox regression. In the multivariable Cox regression analysis, race, age, median income, sex, year of diagnosis, T stage, N stage, scope region lymph surgery, chemotherapy, and radiotherapy were independent predictors for OS of all patients. White, young age of onset, median income over 65,000 USD, female, year of diagnosis between 2011 and 2015, T1 stage, N0 stage, scope region lymph surgery ≥ 4, and received adjuvant chemotherapy and radiotherapy indicated better survival. Furthermore, adjuvant radiotherapy was associated with better survival compared to no-radiotherapy group in univariable Cox regression [no-radiotherapy versus radiotherapy (hazard ratio [HR], 1.24; 95% CI, 1.18 to 1.31; p < 0.01)], and in multivariable Cox regression, adjuvant radiotherapy also showed obvious survival benefit compared with no-radiotherapy [no-radiotherapy versus radiotherapy (HR, 1.20; 95% CI, 1.13 to 1.27; p < 0.01)] (Table 2).
[Figure omitted. See PDF.]
According to the results of univariable Cox analysis for CSS, significant differences were observed in all variables except for sex and scope region lymph surgery. Considering sex and and scope region lymph surgery are independent predictors for OS, the two variables were incorporated along with other factors. Multivariable Cox regression analysis for CSS showed that the factors such as young age of onset, median income over 65,000 USD, year of diagnosis between 2011 and 2015, T1 stage, N0 stage, scope region lymph surgery ≥ 4, and received adjuvant chemotherapy and radiotherapy were associated with improved survival. Moreover, adjuvant radiotherapy demonstrated superior survival outcomes compared to the no-radiotherapy group in both univariable Cox regression analysis [no-radiotherapy versus radiotherapy (HR, 1.21; 95% CI to 1.15 to 1.28; p < 0.01)], and multivariable Cox regression analysis [no-radiotherapy versus radiotherapy (HR, 1.20; 95% CI, 1.13 to 1.28; p < 0.01)] (Table 3).
[Figure omitted. See PDF.]
3.3 Survival outcomes and subgroup analysis after PSM
After PSM, the mOS and mCSS of pancreatic cancer patients were 23 months (95% CI, 21.86 to 24.14) and 24 months (95% CI, 22.73 to 25.27), respectively, in the radiotherapy group. While in the non-radiotherapy group, they were 22 months (95% CI, 20.77 to 23.23) and 23 months (95% CI, 21.58 to 24.42), respectively. No statistically significant difference was observed between the two groups regarding OS and CSS characteristics (all p >0 .05) as shown in Fig 2.
[Figure omitted. See PDF.]
(A) OS; (B) CSS. PSM, propensity score matching; OS, overall survival; CSS, cancer-specific survival.
In the subgroup analysis, regardless of age, marriage, median income, sex, year of diagnosis, or received chemotherapy, radiotherapy did not improve survival of OS (all p > 0.05). The patients in the radiotherapy group with the N0 stage (N-) exhibited a higher all-cause mortality rate and cancer-specific mortality rate compared to the patients without radiotherapy (all p < 0.01) (Table 4). However, among patients with N1 stage (N+), radiotherapy reduced the all-cause mortality rate and cancer-specific mortality rate when compared to no radiotherapy (all p < 0.01, Fig 3). The mOS for radiotherapy and non-radiotherapy were 21 months (95% CI, 19.82 to 22.18) and 18 months (95% CI, 16.88 to 19.12), respectively.
[Figure omitted. See PDF.]
(A) OS; (B) CSS. PSM, propensity score matching; OS, overall survival; CSS, cancer-specific survival.
[Figure omitted. See PDF.]
For patients in the radiotherapy group with pancreatic head cancer, the all-cause mortality rate and cancer-specific mortality rate showed no significant difference compared to those not receiving radiotherapy (p = 0.28 and p = 0.45, respectively). Among the patients with pancreatic body and tail cancer, those in the radiotherapy group exhibited a higher all-cause mortality rate and cancer-specific mortality rate than the patients in the non-radiotherapy group (p = 0.02 and p = 0.01, respectively). Patients with T1 stage in the radiotherapy group exhibited higher all-cause mortality and cancer-specific mortality rates compared to the non-radiotherapy group (p = 0.01 and p < 0.01, respectively). In contrast, patients with the T4 stage who received radiotherapy had lower all-cause mortality rates and cancer-specific mortality rate than the non-radiotherapy group (p = 0.01 and p = 0.02, respectively). Radiotherapy tended to shorten survival of those patients in T2 stage and prolong the survival in T3 stage. However, there were no significant difference (all p > 0.05). Compared with chemotherapy, radiochemotherapy did not bring benefit to OS and CSS of pancreatic cancer patients (all p > 0.05). In no-chemotherapy group, median OS was 17 months (95%CI, 13.99 to 20.01), 16 months (95%CI, 7.96 to 24.04) for patients undergone radiotherapy, non-radiotherapy, respectively (p = 0.08). And median CSS was 19 months (95%CI, 16.000 to 22.000), 19 months (95%CI, 11.27 to 26.74) for patients undergone radiotherapy, non-radiotherapy, respectively (p = 0.04, Table 4).
3.4 Subgroup analysis of survival in lymph node positive patients
Further exploration was conducted on the prognostic impact of radiotherapy on various subgroups of stage N1 (N+) patients. The result showed a survival benefit of radiotherapy among patients with tumors in the head of the pancreas (all p < 0.01), exhibiting a mOS of 22 months versus 19 months and a mCSS of 22 months versus 19 months. In contrast, no significantly difference was noted in the body and tail of pancreatic cancer (p = 0.82 and p = 0.52, respectively). For the T stage subgroup, radiotherapy brought benefit in the T2 stage group (p = 0.03 and p = 0.06, respectively), T3 stage group (all p < 0.01) and T4 stage group (all p = 0.01), while radiotherapy brought no benefit in T1 stage group (p = 0.88 and p = 0.47, respectively). Moreover, the results revealed that both male and female patients with node-positive pancreatic cancer could benefit from radiotherapy, regardless of their gender (p < 0.05). OS and CSS for patients receiving adjuvant radiotherapy was longer than no-radiotherapy in the age ≤ 60 group (all p < 0.01). As for the age 60–70 group and age > 70 group, there was no OS benefit of radiotherapy compared with no-radiotherapy (all p = 0.058). Note that, for the chemotherapy group, radiotherapy also reduced the all-cause and cancer-specific mortality rates (all p < 0.01). But for the no-chemotherapy group, there was no OS and CSS benefit of radiotherapy compared with no-radiotherapy (p = 0.85 and p = 0.39, respectively). The median overall survival time and cancer-specific survival time of N+ group patients were shown in Table 5.
[Figure omitted. See PDF.]
4. Discussion
The incidence of pancreatic cancer is increasing every year, and its prognosis is so poor [12]. Tumor recurrence is common in pancreatic cancer after surgery [13,14], thus, the need for adjuvant comprehensive radiation therapy is essential to improve the patient survival rate. Previous randomized controlled trials and retrospective studies have reported inconsistent results regarding the effect of adjuvant radiotherapy on pancreatic cancer after radical surgery [15–17]. They are susceptible to bias due to numbers of insufficient cases and the lack of detailed screening for radiotherapy benefits in certain retrospective studies. Hence, this study was initiated to examine the role of radiotherapy in pancreatic cancer after up-front radical surgery within a substantial cohort of 7097 observations, aiming to identify which patient could benefit from radiotherapy and which do not.
Significant differences were observed in the patient populations who received adjuvant radiation [18]. Specifically, patients in the radiotherapy group were more likely to be young, married, male, 2004–2010 diagnosed, T3-4 stage, N1 stage, head of the pancreas, and received chemotherapy. Our study demonstrated that younger(age < 60 years), median income greater than 65,000 USD, female, year of diagnosis between 2011 and 2015, T1 stage, N0 stage, scope region lymph surgery ≥ 4, and received adjuvant chemotherapy and radiotherapy were associated with better survival, which was in accordance with previously published findings [19]. Our research indicated that adjuvant radiotherapy brought survival benefits to pancreatic cancer patients after up-front radical surgery before PSM.
After PSM, the KM analysis showed little significant difference that radiotherapy benefits the survival of pancreatic cancer patients after upfront radical surgery. A detailed analysis of the survival curve showed that radiotherapy could offer a survival benefit in the early-stage, while adjuvant radiotherapy increased the risk of mortality in the later stages. This outcome could be related to various factors including late toxicity of radiotherapy, distant metastasis, and other confounders [20]. The analysis led to the hypothesis that while some patients may benefit from adjuvant radiotherapy, others may not, which was confirmed through further subgroup analyses. Subgroup analysis suggested that radiotherapy significantly reduced the risk of death in patients within stage N1 (N+) and T4 groups, while adjuvant radiotherapy posed a risk of death for patients in stage T1, N0, those with tumors in the body and tail of pancreas. When comparing the above findings with other studies, it is important to note that the positive results align while the negative results vary. A retrospective study identified a significant survival advantage for the use of adjuvant radiotherapy over surgery alone or neoadjuvant radiotherapy in treating stage II (T3N0, T1-3N1) pancreatic cancer. Radiotherapy was not associated with survival benefit in stage I (T1-2N0) patients [21]. Meanwhile, another analysis of 10,097 patients with pancreatic adenocarcinoma cancer showed that the survival benefit of adjuvant chemoradiotherapy was more significant in patients with female or T3 or lymph nodes positive [22]. Due to different screening schemes, the results could assist in better identifying individual suitability for choosing adjuvant radiotherapy and who should be cautious about selecting radiotherapy in clinical practice.
Previous research has indicated that adjuvant radiotherapy enhanced survival in resectable pancreatic cancer patients with N1 stage (N+), aligning with established findings [23–25]. However, the subgroup analysis of the adjuvant radiotherapy in N1 stage (N+) pancreatic cancer patients has not been demonstrated. Then, the further analysis of our study found that not all patients with N+ stage could benefit from adjuvant radiotherapy. Notably, patients with tumors located in the head of the pancreas could experience survival benefits, while those with tumors in the body and tail did not. The high metabolic activity of the body and tail of the pancreas, along with the extensive target area for postoperative radiotherapy and its associated significant side effects, counterbalance the potential benefits offered by adjuvant radiotherapy. This observation reflects the different biological behaviors of pancreatic cancer across anatomical sites [19]. A study of pancreatic cancer patients identified a robust gene expression signature associated with tumor location, suggesting that head, body and tail of pancreatic cancer were different [26]. Pancreatic body and tail cancers often present with distant metastases more than pancreatic head cancers [27]. Postoperative local control is less important for pancreatic body and tail cancers than for pancreatic head cancers. Thus, pancreatic cancer is usually treated according to the location. However, tumor location was not an independent prognostic factor for pancreatic cancer after adjusting for potential confounders, which is in line with previous findings [28,29].
The significance of T stage in relation to adjuvant radiotherapy is underscored by the discovery that patients with T2-4N+ stage could potentially benefit from postoperative radiotherapy, whereas those with T1N+ stage did not demonstrate such benefits. The addition of adjuvant radiotherapy did not confer any benefit to T1N1 patients, despite its association with a high R0 removal rate in early-stage patients. However, it was found to increase the incidence of radiotherapy toxicity [30]. This result diverge from some studies that suggest postoperative adjuvant radiotherapy has a better prognosis, and adjuvant radiotherapy is also preferred for pancreatic cancer patients with stage T1N1M0 [31]. This result potentially due to the lack of comprehensive subgroup analyses across different T stages in prior research. Instead, additional studies on neoadjuvant chemoradiotherapy have been added. Radiotherapy was found to benefit N+ stage patients irrespective of sex. Meanwhile, Age is the reference factor to guide the selection of radiotherapy for patients with stage IIB/III pancreatic cancer [32]. As for the age factor, our study showed that all N+ stage patients could benefit from adjuvant radiotherapy except for the the age > 60 groups. This result suggests that radiotherapy for age > 60 patients should be approached with caution due to increased risks. We speculate that this might be due to lack of standard treatment regimens and dosages of radiotherapy. The elderly might not receive standard chemotherapy at the time of radiotherapy [33]. Compared to chemotherapy alone, chemoradiotherapy significantly improved the outcome for N+ stage patients. For the patients in the non-chem group, however, radiotherapy did not bring better survival. This finding could be explained that adjuvant chemotherapy plays an crucial role in postoperative pancreatic cancer. Chemotherapy is the cornerstone of postoperative adjuvant therapy for resectable pancreatic cancer [34].
The study presents several limitations. It is retrospective in nature, which could introduce selectivity bias in the data collection process. Patients were diagnosed as pancreatic cancer according to the Sixth Edition of the AJCC staging manual, which is slightly different from the eighth edition staging currently used. Moreover, all the data were exclusively collected from the SEER database, which lacked detailed chemotherapy and radiotherapy protocol, incisal edge information, and physical fitness scores. To enhance the robustness of these concerns, it is recommended that further clinical trials should be undertaken on the following issues: (1) With the advancement of precision radiotherapy, there is a growing need to further explore the radiotherapy target area and dose fraction for postoperative radiotherapy in pancreatic cancer. This exploration should be based on improved effectiveness and safety, aiming to enhance its role in postoperative adjuvant therapy for pancreatic cancer. (2) To investigate the feasibility of incorporating postoperative adjuvant radiotherapy in specific subgroups where achieving local control can lead to survival benefits.
5. Conclusion
The analysis demonstrates that N1 stage (N+) pancreatic cancer patients who have received the up-front radical surgery with T2-4 stage, primary focus on the head of the pancreas, young age of onset, and with combination of chemotherapy may benefit from adjuvant radiotherapy. In contrast, radiotherapy should be approached with caution for patients at the T1 stage and N0 stage (N-), especially when the tumor is located on the body and tail of the pancreas. These insights may contribute to the development of individualized adjuvant radiotherapy for pancreatic cancer patients following up-front radical surgery.
Acknowledgments
The authors thank the volunteers for their participation in these studies.
References
1. 1. Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395(10242):2008–2020. pmid:32593337.
* View Article
* PubMed/NCBI
* Google Scholar
2. 2. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49. Epub 2024 Jan 17. Erratum in: CA Cancer J Clin. 2024 Mar-Apr;74(2):203. pmid:38230766.
* View Article
* PubMed/NCBI
* Google Scholar
3. 3. Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–1024. Epub 2017 Jan 25. pmid:28129987.
* View Article
* PubMed/NCBI
* Google Scholar
4. 4. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 1987;59(12):2006–10. pmid:3567862.
* View Article
* PubMed/NCBI
* Google Scholar
5. 5. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776–82; discussion 782–4. pmid:10615932; PMCID: PMC1420941.
* View Article
* PubMed/NCBI
* Google Scholar
6. 6. Garofalo MC, Regine WF, Tan MT. On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer. Ann Surg. 2006;244(2):332–3; author reply 333. pmid:16858208; PMCID: PMC1602155.
* View Article
* PubMed/NCBI
* Google Scholar
7. 7. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004; 350(12):1200–10. Erratum in: N Engl J Med. 2004 Aug 12;351(7):726. pmid:15028824.
* View Article
* PubMed/NCBI
* Google Scholar
8. 8. Wu L, Xu Y, Zhou Y, Zeng Z, Fan Y, Wang D, et al. Additional adjuvant radiotherapy improves survival at 1 year after surgical treatment for pancreatic cancer patients with T4, N2 disease, positive resection margin, and receiving adjuvant chemotherapy. Front Oncol. 2023;13:1109068. pmid:37534251; PMCID: PMC10391548.
* View Article
* PubMed/NCBI
* Google Scholar
9. 9. Kamarajah SK, Sonnenday CJ, Cho CS, Frankel TL, Bednar F, Lawrence TS, et al. Association of Adjuvant Radiotherapy With Survival After Margin-negative Resection of Pancreatic Ductal Adenocarcinoma: A Propensity-matched National Cancer Database (NCDB) Analysis. Ann Surg. 2021;273(3):587–594. pmid:30817352.
* View Article
* PubMed/NCBI
* Google Scholar
10. 10. Moaven O, Clark CJ, Russell GB, Votanopoulos KI, Howerton R, Levine EA, et al. Optimal Adjuvant Treatment Approach After Upfront Resection of Pancreatic Cancer: Revisiting the Role of Radiation Based on Pathologic Features. Ann Surg. 2021;274(6):1058–1066. pmid:31913868; PMCID: PMC7335684.
* View Article
* PubMed/NCBI
* Google Scholar
11. 11. Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(4):439–457. pmid:33845462.
* View Article
* PubMed/NCBI
* Google Scholar
12. 12. Drouillard A, Manfredi S, Lepage C, Bouvier AM. Épidémiologie du cancer du pancréas [Epidemiology of pancreatic cancer]. Bull Cancer. 2018;105(1):63–69. French. Epub 2017 Dec 19. pmid:29273548.
* View Article
* PubMed/NCBI
* Google Scholar
13. 13. Kolbeinsson H, Hoppe A, Bayat A, Kogelschatz B, Mbanugo C, Chung M, et al. Recurrence patterns and postrecurrence survival after curative intent resection for pancreatic ductal adenocarcinoma. Surgery. 2021;169(3):649–654. Epub 2020 Aug 15. pmid:32807504.
* View Article
* PubMed/NCBI
* Google Scholar
14. 14. Welsch T, Büchler MW, Schmidt J. Chirurgie des Pankreaskarzinoms [Surgery for pancreatic cancer]. Z Gastroenterol. 2008;46(12):1393–403. German. Epub 2008 Dec 3. pmid:19053009.
* View Article
* PubMed/NCBI
* Google Scholar
15. 15. Sugawara A, Kunieda E. Effect of adjuvant radiotherapy on survival in resected pancreatic cancer: a propensity score surveillance, epidemiology, and end results database analysis. J Surg Oncol. 2014;110(8):960–6. Epub 2014 Aug 21. pmid:25146251.
* View Article
* PubMed/NCBI
* Google Scholar
16. 16. Lin ZB, Song JY, Li AC, Chen C, Huang XX, Xu BH. The benefit of adjuvant radiotherapy on overall survival in resected stage I to II pancreatic cancer: A propensity-adjusted analysis. PLoS One. 2020;15(12):e0243170. pmid:33315874; PMCID: PMC7735624.
* View Article
* PubMed/NCBI
* Google Scholar
17. 17. Klautke G, Brunner TB. Radiotherapy in pancreatic cancer. Strahlenther Onkol. 2008;184(11):557–64. Epub 2008 Nov 19. pmid:19016013.
* View Article
* PubMed/NCBI
* Google Scholar
18. 18. Baig MZ, Filkins A, Khan M, Saif MW, Aziz H. Survival Benefits and Disparities in Adjuvant Radiation Therapy for Patients with Pancreatic Cancer. JOP. 2021;22(2):36–41. Epub 2021 Mar 30. pmid:34354555; PMCID: PMC8336069.
* View Article
* PubMed/NCBI
* Google Scholar
19. 19. Artinyan A, Soriano PA, Prendergast C, Low T, Ellenhorn JD, Kim J. The anatomic location of pancreatic cancer is a prognostic factor for survival. HPB (Oxford). 2008;10(5):371–6. pmid:18982154; PMCID: PMC2575681.
* View Article
* PubMed/NCBI
* Google Scholar
20. 20. Wu L, Lu Y, Chen L, Yue X, Cen C, Zheng C, et al. The Effects of Radiotherapy on Pancreatic Ductal Adenocarcinoma in Patients with Liver Metastases. Curr Oncol. 2022;29(10):7912–7924. pmid:36290902; PMCID: PMC9600493.
* View Article
* PubMed/NCBI
* Google Scholar
21. 21. Han D, Gao F, Liu JL, Wang H, Fu Q, Yang GW. Analysis of radiotherapy impact on survival in resected stage I/II pancreatic cancer patients: a population-based study. BMC Cancer. 2021;21(1):560. pmid:34001035; PMCID: PMC8130297.
* View Article
* PubMed/NCBI
* Google Scholar
22. 22. Shi X, Peng J, Jiang H, Gao Y, Wang W, Zhou F. Impact of Adjuvant Chemoradiotherapy on Survival of Resected Pancreatic Adenocarcinoma Cancer: A Surveillance, Epidemiology and End Results (SEER) Analysis. Front Oncol. 2021;11:651671. pmid:34277405; PMCID: PMC8281351.
* View Article
* PubMed/NCBI
* Google Scholar
23. 23. Xing J, Yang B, Hou X, Jia N, Gong X, Li X, et al. Prognostic Factors and Effect of Adjuvant Chemoradiation Following Chemotherapy in Resected Pancreatic Cancer Patients With Lymph Node Metastasis or R1 Resection. Front Oncol. 2021;11:660215. pmid:34631515; PMCID: PMC8493064.
* View Article
* PubMed/NCBI
* Google Scholar
24. 24. Mellon EA, Springett GM, Hoffe SE, Hodul P, Malafa MP, Meredith KL, et al. Adjuvant radiotherapy and lymph node dissection in pancreatic cancer treated with surgery and chemotherapy. Cancer. 2014;120(8):1171–7. Epub 2014 Jan 3. pmid:24390779.
* View Article
* PubMed/NCBI
* Google Scholar
25. 25. Altman AM, White MJ, Marmor S, Shukla D, Chang K, Lou E, et al. The Addition of Chemoradiation to Adjuvant Chemotherapy is Associated With Improved Survival Following Upfront Surgical Resection for Pancreatic Cancer With Nodal Metastases. Cancer Control. 2022;29:10732748221109991. pmid:35839251; PMCID: PMC9290159.
* View Article
* PubMed/NCBI
* Google Scholar
26. 26. Birnbaum DJ, Bertucci F, Finetti P, Birnbaum D, Mamessier E. Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors. Cancers (Basel). 2019;11(4):497. pmid:30965637; PMCID: PMC6520848.
* View Article
* PubMed/NCBI
* Google Scholar
27. 27. van Erning FN, Mackay TM, van der Geest LGM, Groot Koerkamp B, van Laarhoven HWM, Bonsing BA, et al. Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis. Acta Oncol. 2018;57(12):1655–1662. Epub 2018 Sep 28. pmid:30264642.
* View Article
* PubMed/NCBI
* Google Scholar
28. 28. Lee M, Kwon W, Kim H, Byun Y, Han Y, Kang JS, et al. The Role of Location of Tumor in the Prognosis of the Pancreatic Cancer. Cancers (Basel). 2020;12(8):2036. pmid:32722142; PMCID: PMC7465041.
* View Article
* PubMed/NCBI
* Google Scholar
29. 29. Sung MK, Park Y, Kwak BJ, Jun E, Lee W, Song KB, et al. Comparison of Characteristics and Survival Rates of Resectable Pancreatic Ductal Adenocarcinoma according to Tumor Location. Biomedicines. 2021;9(11):1706. pmid:34829935; PMCID: PMC8615679.
* View Article
* PubMed/NCBI
* Google Scholar
30. 30. Franko J, Hugec V, Lopes TL, Goldman CD. Survival among pancreaticoduodenectomy patients treated for pancreatic head cancer <1 or 2 cm. Ann Surg Oncol. 2013;20(2):357–61. Epub 2012 Sep 1. pmid:22941171.
* View Article
* PubMed/NCBI
* Google Scholar
31. 31. Wang D, Liu C, Zhou Y, Yan T, Li C, Yang Q, et al. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis. Radiat Oncol. 2020;15(1):107. pmid:32404114; PMCID: PMC7222314.
* View Article
* PubMed/NCBI
* Google Scholar
32. 32. Wang D, Ge H, Tian M, Li C, Zhao L, Pei Q, et al. The Survival Effect of Radiotherapy on Stage IIB/III Pancreatic Cancer Undergone Surgery in Different Age and Tumor Site Groups: A Propensity Scores Matching Analysis Based on SEER Database. Front Oncol. 2022;12:799930. pmid:35174085; PMCID: PMC8841859.
* View Article
* PubMed/NCBI
* Google Scholar
33. 33. Di Capua B, Bellieni A, Fusco D, Gambacorta MA, Tagliaferri L, Villani ER, et al. Perspectives and limits of cancer treatment in an oldest old population. Aging Clin Exp Res. 2021;33(10):2831–2837. Epub 2021 Mar 11. pmid:33704699; PMCID: PMC8531055.
* View Article
* PubMed/NCBI
* Google Scholar
34. 34. Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–81. pmid:24104372.
* View Article
* PubMed/NCBI
* Google Scholar
Citation: Xiao X, Huang P, Xu X-T (2025) The choice of adjuvant radiotherapy in pancreatic cancer patients after up-front radical surgery. PLoS ONE 20(1): e0317995. https://doi.org/10.1371/journal.pone.0317995
About the Authors:
Xia Xiao
Roles: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Writing – original draft
Affiliations: Department of Oncology, Wuxi No.2 People’ s Hospital, Jiangnan University Medical Center, Wuxi, Jiangsu Province, China, Department of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
ORICD: https://orcid.org/0000-0001-6168-2963
Pei Huang
Roles: Project administration, Supervision, Validation, Visualization
Affiliation: Department of Oncology, Wuxi No.2 People’ s Hospital, Jiangnan University Medical Center, Wuxi, Jiangsu Province, China
Xiao-Ting Xu
Roles: Supervision, Validation, Visualization, Writing – review & editing
E-mail: [email protected]
Affiliation: Department of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
1. Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395(10242):2008–2020. pmid:32593337.
2. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12–49. Epub 2024 Jan 17. Erratum in: CA Cancer J Clin. 2024 Mar-Apr;74(2):203. pmid:38230766.
3. Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–1024. Epub 2017 Jan 25. pmid:28129987.
4. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 1987;59(12):2006–10. pmid:3567862.
5. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776–82; discussion 782–4. pmid:10615932; PMCID: PMC1420941.
6. Garofalo MC, Regine WF, Tan MT. On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer. Ann Surg. 2006;244(2):332–3; author reply 333. pmid:16858208; PMCID: PMC1602155.
7. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004; 350(12):1200–10. Erratum in: N Engl J Med. 2004 Aug 12;351(7):726. pmid:15028824.
8. Wu L, Xu Y, Zhou Y, Zeng Z, Fan Y, Wang D, et al. Additional adjuvant radiotherapy improves survival at 1 year after surgical treatment for pancreatic cancer patients with T4, N2 disease, positive resection margin, and receiving adjuvant chemotherapy. Front Oncol. 2023;13:1109068. pmid:37534251; PMCID: PMC10391548.
9. Kamarajah SK, Sonnenday CJ, Cho CS, Frankel TL, Bednar F, Lawrence TS, et al. Association of Adjuvant Radiotherapy With Survival After Margin-negative Resection of Pancreatic Ductal Adenocarcinoma: A Propensity-matched National Cancer Database (NCDB) Analysis. Ann Surg. 2021;273(3):587–594. pmid:30817352.
10. Moaven O, Clark CJ, Russell GB, Votanopoulos KI, Howerton R, Levine EA, et al. Optimal Adjuvant Treatment Approach After Upfront Resection of Pancreatic Cancer: Revisiting the Role of Radiation Based on Pathologic Features. Ann Surg. 2021;274(6):1058–1066. pmid:31913868; PMCID: PMC7335684.
11. Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(4):439–457. pmid:33845462.
12. Drouillard A, Manfredi S, Lepage C, Bouvier AM. Épidémiologie du cancer du pancréas [Epidemiology of pancreatic cancer]. Bull Cancer. 2018;105(1):63–69. French. Epub 2017 Dec 19. pmid:29273548.
13. Kolbeinsson H, Hoppe A, Bayat A, Kogelschatz B, Mbanugo C, Chung M, et al. Recurrence patterns and postrecurrence survival after curative intent resection for pancreatic ductal adenocarcinoma. Surgery. 2021;169(3):649–654. Epub 2020 Aug 15. pmid:32807504.
14. Welsch T, Büchler MW, Schmidt J. Chirurgie des Pankreaskarzinoms [Surgery for pancreatic cancer]. Z Gastroenterol. 2008;46(12):1393–403. German. Epub 2008 Dec 3. pmid:19053009.
15. Sugawara A, Kunieda E. Effect of adjuvant radiotherapy on survival in resected pancreatic cancer: a propensity score surveillance, epidemiology, and end results database analysis. J Surg Oncol. 2014;110(8):960–6. Epub 2014 Aug 21. pmid:25146251.
16. Lin ZB, Song JY, Li AC, Chen C, Huang XX, Xu BH. The benefit of adjuvant radiotherapy on overall survival in resected stage I to II pancreatic cancer: A propensity-adjusted analysis. PLoS One. 2020;15(12):e0243170. pmid:33315874; PMCID: PMC7735624.
17. Klautke G, Brunner TB. Radiotherapy in pancreatic cancer. Strahlenther Onkol. 2008;184(11):557–64. Epub 2008 Nov 19. pmid:19016013.
18. Baig MZ, Filkins A, Khan M, Saif MW, Aziz H. Survival Benefits and Disparities in Adjuvant Radiation Therapy for Patients with Pancreatic Cancer. JOP. 2021;22(2):36–41. Epub 2021 Mar 30. pmid:34354555; PMCID: PMC8336069.
19. Artinyan A, Soriano PA, Prendergast C, Low T, Ellenhorn JD, Kim J. The anatomic location of pancreatic cancer is a prognostic factor for survival. HPB (Oxford). 2008;10(5):371–6. pmid:18982154; PMCID: PMC2575681.
20. Wu L, Lu Y, Chen L, Yue X, Cen C, Zheng C, et al. The Effects of Radiotherapy on Pancreatic Ductal Adenocarcinoma in Patients with Liver Metastases. Curr Oncol. 2022;29(10):7912–7924. pmid:36290902; PMCID: PMC9600493.
21. Han D, Gao F, Liu JL, Wang H, Fu Q, Yang GW. Analysis of radiotherapy impact on survival in resected stage I/II pancreatic cancer patients: a population-based study. BMC Cancer. 2021;21(1):560. pmid:34001035; PMCID: PMC8130297.
22. Shi X, Peng J, Jiang H, Gao Y, Wang W, Zhou F. Impact of Adjuvant Chemoradiotherapy on Survival of Resected Pancreatic Adenocarcinoma Cancer: A Surveillance, Epidemiology and End Results (SEER) Analysis. Front Oncol. 2021;11:651671. pmid:34277405; PMCID: PMC8281351.
23. Xing J, Yang B, Hou X, Jia N, Gong X, Li X, et al. Prognostic Factors and Effect of Adjuvant Chemoradiation Following Chemotherapy in Resected Pancreatic Cancer Patients With Lymph Node Metastasis or R1 Resection. Front Oncol. 2021;11:660215. pmid:34631515; PMCID: PMC8493064.
24. Mellon EA, Springett GM, Hoffe SE, Hodul P, Malafa MP, Meredith KL, et al. Adjuvant radiotherapy and lymph node dissection in pancreatic cancer treated with surgery and chemotherapy. Cancer. 2014;120(8):1171–7. Epub 2014 Jan 3. pmid:24390779.
25. Altman AM, White MJ, Marmor S, Shukla D, Chang K, Lou E, et al. The Addition of Chemoradiation to Adjuvant Chemotherapy is Associated With Improved Survival Following Upfront Surgical Resection for Pancreatic Cancer With Nodal Metastases. Cancer Control. 2022;29:10732748221109991. pmid:35839251; PMCID: PMC9290159.
26. Birnbaum DJ, Bertucci F, Finetti P, Birnbaum D, Mamessier E. Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors. Cancers (Basel). 2019;11(4):497. pmid:30965637; PMCID: PMC6520848.
27. van Erning FN, Mackay TM, van der Geest LGM, Groot Koerkamp B, van Laarhoven HWM, Bonsing BA, et al. Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis. Acta Oncol. 2018;57(12):1655–1662. Epub 2018 Sep 28. pmid:30264642.
28. Lee M, Kwon W, Kim H, Byun Y, Han Y, Kang JS, et al. The Role of Location of Tumor in the Prognosis of the Pancreatic Cancer. Cancers (Basel). 2020;12(8):2036. pmid:32722142; PMCID: PMC7465041.
29. Sung MK, Park Y, Kwak BJ, Jun E, Lee W, Song KB, et al. Comparison of Characteristics and Survival Rates of Resectable Pancreatic Ductal Adenocarcinoma according to Tumor Location. Biomedicines. 2021;9(11):1706. pmid:34829935; PMCID: PMC8615679.
30. Franko J, Hugec V, Lopes TL, Goldman CD. Survival among pancreaticoduodenectomy patients treated for pancreatic head cancer <1 or 2 cm. Ann Surg Oncol. 2013;20(2):357–61. Epub 2012 Sep 1. pmid:22941171.
31. Wang D, Liu C, Zhou Y, Yan T, Li C, Yang Q, et al. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis. Radiat Oncol. 2020;15(1):107. pmid:32404114; PMCID: PMC7222314.
32. Wang D, Ge H, Tian M, Li C, Zhao L, Pei Q, et al. The Survival Effect of Radiotherapy on Stage IIB/III Pancreatic Cancer Undergone Surgery in Different Age and Tumor Site Groups: A Propensity Scores Matching Analysis Based on SEER Database. Front Oncol. 2022;12:799930. pmid:35174085; PMCID: PMC8841859.
33. Di Capua B, Bellieni A, Fusco D, Gambacorta MA, Tagliaferri L, Villani ER, et al. Perspectives and limits of cancer treatment in an oldest old population. Aging Clin Exp Res. 2021;33(10):2831–2837. Epub 2021 Mar 11. pmid:33704699; PMCID: PMC8531055.
34. Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–81. pmid:24104372.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2025 Xiao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
Background
The role of adjuvant radiotherapy in pancreatic cancer following radical surgery remains a subject of of controversy. This study aimed to more accurately screen pancreatic patients who benefit from adjuvant radiotherapy.
Methods
Clinicopathologic characteristics of patients with resectable pancreatic cancer were collected from the Surveillance, Epidemiology, and End Results (SEER) database (2004–2015). Univariate and multivariate analyses were applied to identify prognostic factors affecting patient survival. All the patients were divided into two groups, one receiving radiation and the other not. Selection bias were reduced by propensity-score matching (PSM). Kaplan-Meier analysis was used to estimate overall survival (OS) and cancer-specific survival (CSS) between the two groups.
Results
Within 7097 patients, 2276 received adjuvant radiotherapy (external beam radiation), and 4821 did not. Multivariate analysis revealed that race, age, median income, sex, year of diagnosis, American Joint Committee on Cancer (AJCC) T stage, N stage, scope region lymph surgery, chemotherapy, and radiotherapy were independent predictors for overall survival of all the patients (all p < 0.05). After PSM, a total of 4304 patients were included. There was no OS and CSS benefit of radiotherapy compared with no-radiotherapy (all p > 0.05). Among patients with N1 stage, the radiotherapy group exhibited a median overall survival (mOS) of 21 months (95% CI, 19.82 to 22.18), while the non-radiotherapy group showed a slightly lower mOS of 18 months (95% CI, 16.88 to 19.12). Similarly, in terms of median cancer-specific survival (mCSS), the radiotherapy group demonstrated a mCSS of 22 months (95% CI, 20.79 to 23.21), whereas the non-radiotherapy group had a slightly shorter mCSS of 19 months (95% CI, 17.81 to 20.19). Radiotherapy reduced the all-cause mortality rate and cancer-specific mortality rate among patients with the N1 stage and T4 stage (all p < 0.05). In contrast, the patients in the radiotherapy group with the N0 stage (mOS, 28 months versus 34 months; mCSS, 30 months versus 41months), or primary focus on the body and tail of the pancreas (mOS, 23 months versus 29 months; mCSS, 25 months versus 32 months), or T1 stage (mOS, 36 months versus 113 months; mCSS, 36 months versus 104 months) exhibited a higher all-cause mortality rate and cancer-specific mortality rate compared to those without radiotherapy (all p < 0.05). Subgroup analysis indicated N1 stage pancreatic cancer patients with T2-4 stage, primary focus on the head of the pancreas, young age of onset, and combination chemotherapy were in favor of the adjuvant radiotherapy group (all p < 0.05).
Conclusions
Our analysis demonstrates that adjuvant radiotherapy may be beneficial for N1 stage (N+) pancreatic cancer patients who have undergone up-front radical surgery with T2-4 stage, primary focus on the head of the pancreas, young age of onset, and receiving combination chemotherapy. However, radiotherapy needs to be used with caution in patients with T1 stage, N0 stage (N-), or primary focus on the body and tail of the pancreas. These findings may contribute to the development of personalized selection criteria for adjuvant radiotherapy in post-surgical pancreatic cancer patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Huang, Pei; Xiao-Ting, Xu